Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia

J. Brice Weinberg, Alicia D. Volkheimer, Youwei Chen, Bethany E. Beasley, Ning Jiang, Mark C. Lanasa, Daphne Friedman, Gina Vaccaro, Catherine W. Rehder, Carlos M. DeCastro, David A. Rizzieri, Louis F. Diehl, Jon P. Gockerman, Joseph O. Moore, Barbara K. Goodman, Marc C. Levesque

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgVH) mutation status, cytogenetic abnormalities, and leukemia cell CD38 and Zap-70 to older, traditional parameters. We also wanted to construct a simple, inexpensive prognosis score that would significantly predict TTT and survival in patients at the time of diagnosis and help practicing clinicians. In univariate analyses, patients with higher clinical stage, higher leukocyte count at diagnosis, shorter leukocyte doubling time, elevated serum lactate dehydrogenase (LDH), unmutated immunoglobulin heavy chain variable region (IgVH) genes, and higher CD38 had a shorter overall survival and time-to-treatment (TTT). CLL cell Zap-70 expression was higher in patients with unmutated IgV H, and those with higher Zap-70 tended to have shorter survival. IgVH4-34 or IgVH1-69 was the most common IgVH genes used (16 and 12%, respectively). Of those with IgVH1-69, 86% had unmutated IgVH and had a significantly shorter TTT. A cytogenetic abnormality was noted in 71% of the patients tested. Patients with 11q22 del and 17p13 del or complex abnormalities were significantly more likely to have unmutated IgVH. We found that a prognostic score constructed using modified Rai stage, cellular CD38, and serum LDH (parameters easily obtained clinically) significantly predicted TTT and survival in patients at the time of diagnosis and performed as well or better than models using the newer markers.

Original languageEnglish (US)
Pages (from-to)1063-1070
Number of pages8
JournalAmerican Journal of Hematology
Volume82
Issue number12
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Survival
Immunoglobulin Heavy Chains
L-Lactate Dehydrogenase
Chromosome Aberrations
Therapeutics
Serum
Leukocyte Count
Genes
Leukemia
Leukocytes
Mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Weinberg, J. B., Volkheimer, A. D., Chen, Y., Beasley, B. E., Jiang, N., Lanasa, M. C., ... Levesque, M. C. (2007). Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. American Journal of Hematology, 82(12), 1063-1070. https://doi.org/10.1002/ajh.20987

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. / Weinberg, J. Brice; Volkheimer, Alicia D.; Chen, Youwei; Beasley, Bethany E.; Jiang, Ning; Lanasa, Mark C.; Friedman, Daphne; Vaccaro, Gina; Rehder, Catherine W.; DeCastro, Carlos M.; Rizzieri, David A.; Diehl, Louis F.; Gockerman, Jon P.; Moore, Joseph O.; Goodman, Barbara K.; Levesque, Marc C.

In: American Journal of Hematology, Vol. 82, No. 12, 12.2007, p. 1063-1070.

Research output: Contribution to journalArticle

Weinberg, JB, Volkheimer, AD, Chen, Y, Beasley, BE, Jiang, N, Lanasa, MC, Friedman, D, Vaccaro, G, Rehder, CW, DeCastro, CM, Rizzieri, DA, Diehl, LF, Gockerman, JP, Moore, JO, Goodman, BK & Levesque, MC 2007, 'Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia', American Journal of Hematology, vol. 82, no. 12, pp. 1063-1070. https://doi.org/10.1002/ajh.20987
Weinberg, J. Brice ; Volkheimer, Alicia D. ; Chen, Youwei ; Beasley, Bethany E. ; Jiang, Ning ; Lanasa, Mark C. ; Friedman, Daphne ; Vaccaro, Gina ; Rehder, Catherine W. ; DeCastro, Carlos M. ; Rizzieri, David A. ; Diehl, Louis F. ; Gockerman, Jon P. ; Moore, Joseph O. ; Goodman, Barbara K. ; Levesque, Marc C. / Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. In: American Journal of Hematology. 2007 ; Vol. 82, No. 12. pp. 1063-1070.
@article{3c46b3e008744bfeb6de5800958061a1,
title = "Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia",
abstract = "Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgVH) mutation status, cytogenetic abnormalities, and leukemia cell CD38 and Zap-70 to older, traditional parameters. We also wanted to construct a simple, inexpensive prognosis score that would significantly predict TTT and survival in patients at the time of diagnosis and help practicing clinicians. In univariate analyses, patients with higher clinical stage, higher leukocyte count at diagnosis, shorter leukocyte doubling time, elevated serum lactate dehydrogenase (LDH), unmutated immunoglobulin heavy chain variable region (IgVH) genes, and higher CD38 had a shorter overall survival and time-to-treatment (TTT). CLL cell Zap-70 expression was higher in patients with unmutated IgV H, and those with higher Zap-70 tended to have shorter survival. IgVH4-34 or IgVH1-69 was the most common IgVH genes used (16 and 12{\%}, respectively). Of those with IgVH1-69, 86{\%} had unmutated IgVH and had a significantly shorter TTT. A cytogenetic abnormality was noted in 71{\%} of the patients tested. Patients with 11q22 del and 17p13 del or complex abnormalities were significantly more likely to have unmutated IgVH. We found that a prognostic score constructed using modified Rai stage, cellular CD38, and serum LDH (parameters easily obtained clinically) significantly predicted TTT and survival in patients at the time of diagnosis and performed as well or better than models using the newer markers.",
author = "Weinberg, {J. Brice} and Volkheimer, {Alicia D.} and Youwei Chen and Beasley, {Bethany E.} and Ning Jiang and Lanasa, {Mark C.} and Daphne Friedman and Gina Vaccaro and Rehder, {Catherine W.} and DeCastro, {Carlos M.} and Rizzieri, {David A.} and Diehl, {Louis F.} and Gockerman, {Jon P.} and Moore, {Joseph O.} and Goodman, {Barbara K.} and Levesque, {Marc C.}",
year = "2007",
month = "12",
doi = "10.1002/ajh.20987",
language = "English (US)",
volume = "82",
pages = "1063--1070",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia

AU - Weinberg, J. Brice

AU - Volkheimer, Alicia D.

AU - Chen, Youwei

AU - Beasley, Bethany E.

AU - Jiang, Ning

AU - Lanasa, Mark C.

AU - Friedman, Daphne

AU - Vaccaro, Gina

AU - Rehder, Catherine W.

AU - DeCastro, Carlos M.

AU - Rizzieri, David A.

AU - Diehl, Louis F.

AU - Gockerman, Jon P.

AU - Moore, Joseph O.

AU - Goodman, Barbara K.

AU - Levesque, Marc C.

PY - 2007/12

Y1 - 2007/12

N2 - Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgVH) mutation status, cytogenetic abnormalities, and leukemia cell CD38 and Zap-70 to older, traditional parameters. We also wanted to construct a simple, inexpensive prognosis score that would significantly predict TTT and survival in patients at the time of diagnosis and help practicing clinicians. In univariate analyses, patients with higher clinical stage, higher leukocyte count at diagnosis, shorter leukocyte doubling time, elevated serum lactate dehydrogenase (LDH), unmutated immunoglobulin heavy chain variable region (IgVH) genes, and higher CD38 had a shorter overall survival and time-to-treatment (TTT). CLL cell Zap-70 expression was higher in patients with unmutated IgV H, and those with higher Zap-70 tended to have shorter survival. IgVH4-34 or IgVH1-69 was the most common IgVH genes used (16 and 12%, respectively). Of those with IgVH1-69, 86% had unmutated IgVH and had a significantly shorter TTT. A cytogenetic abnormality was noted in 71% of the patients tested. Patients with 11q22 del and 17p13 del or complex abnormalities were significantly more likely to have unmutated IgVH. We found that a prognostic score constructed using modified Rai stage, cellular CD38, and serum LDH (parameters easily obtained clinically) significantly predicted TTT and survival in patients at the time of diagnosis and performed as well or better than models using the newer markers.

AB - Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgVH) mutation status, cytogenetic abnormalities, and leukemia cell CD38 and Zap-70 to older, traditional parameters. We also wanted to construct a simple, inexpensive prognosis score that would significantly predict TTT and survival in patients at the time of diagnosis and help practicing clinicians. In univariate analyses, patients with higher clinical stage, higher leukocyte count at diagnosis, shorter leukocyte doubling time, elevated serum lactate dehydrogenase (LDH), unmutated immunoglobulin heavy chain variable region (IgVH) genes, and higher CD38 had a shorter overall survival and time-to-treatment (TTT). CLL cell Zap-70 expression was higher in patients with unmutated IgV H, and those with higher Zap-70 tended to have shorter survival. IgVH4-34 or IgVH1-69 was the most common IgVH genes used (16 and 12%, respectively). Of those with IgVH1-69, 86% had unmutated IgVH and had a significantly shorter TTT. A cytogenetic abnormality was noted in 71% of the patients tested. Patients with 11q22 del and 17p13 del or complex abnormalities were significantly more likely to have unmutated IgVH. We found that a prognostic score constructed using modified Rai stage, cellular CD38, and serum LDH (parameters easily obtained clinically) significantly predicted TTT and survival in patients at the time of diagnosis and performed as well or better than models using the newer markers.

UR - http://www.scopus.com/inward/record.url?scp=36749001049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749001049&partnerID=8YFLogxK

U2 - 10.1002/ajh.20987

DO - 10.1002/ajh.20987

M3 - Article

C2 - 17654680

AN - SCOPUS:36749001049

VL - 82

SP - 1063

EP - 1070

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -